---
title: "After losing the bid for Metsera to Pfizer, Novo Nordisk AS CEO sets sights on new targets"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/265036602.md"
description: "Novo Nordisk AS CEO will continue to focus on opportunities in the fields of obesity and diabetes after the failed acquisition of Metsera. The company stated that Metsera was viewed as a complementary transaction, and it will evaluate business development and acquisition opportunities that meet return and capital allocation criteria in the future to achieve its strategic goals"
datetime: "2025-11-09T21:33:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265036602.md)
  - [en](https://longbridge.com/en/news/265036602.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265036602.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/265036602.md) | [English](https://longbridge.com/en/news/265036602.md)


# After losing the bid for Metsera to Pfizer, Novo Nordisk AS CEO sets sights on new targets

According to informed sources, Novo Nordisk AS, the owner of Wegovy and Ozempic, will continue to focus on business opportunities in the fields of obesity, diabetes, and their related complications. The company has viewed Metsera Inc. as a potential complementary transaction rather than a transformative acquisition. Novo Nordisk AS stated in a statement that the company will "evaluate business development and acquisition opportunities that meet its return and capital allocation criteria and can further achieve its strategic goals."

### 相關股票

- [Metsera (MTSR.US)](https://longbridge.com/zh-HK/quote/MTSR.US.md)
- [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-HK/quote/NVO.US.md)

## 相關資訊與研究

- [Triple-G Agonist UBT251 Lowers HbA1c By Up To 2.16% In Chinese Phase 2 Diabetes Trial](https://longbridge.com/zh-HK/news/280461871.md)
- [Novo Nordisk A/S Approves Board Changes](https://longbridge.com/zh-HK/news/280694583.md)
- [<![CDATA[Novo Nordisk Launches Multi-Month Subscription Program for Wegovy ]]>](https://longbridge.com/zh-HK/news/281216333.md)
- [BREAKINGVIEWS-Novo Nordisk is Denmark’s big little problem: podcast](https://longbridge.com/zh-HK/news/280570178.md)
- [Novo Nordisk slashes Wegovy prices to court uninsured patients](https://longbridge.com/zh-HK/news/281206892.md)